Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. Stage 2 of Ph 2 combination trial with bemcentinib/KEYTRUDA in NSCLC expected in 1H19. Bemcentinib/TARCEVA Ph 2 combination trial in first line EGFRm patients reported that median PFS surpassed TARCEVA monotherapy.
Jonas Lies vei 91
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by